Previous Close | 6.61 |
Open | 6.80 |
Bid | 6.29 x 2200 |
Ask | 6.86 x 900 |
Day's Range | 6.28 - 6.93 |
52 Week Range | 6.20 - 51.21 |
Volume | |
Avg. Volume | 1,032,660 |
Market Cap | 324.333M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.81 |
Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 29.64 |
WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT8634, an orally bioavailable BiDAC™ degrader targeting BRD9 for the treatment of SMARCB1-perturbed cancers, includin
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C – – Phase 1/2 Clinical Trial Initiated for CFT8634, a BRD9 Degrader, for Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors – – Potential of TORPEDO® Platform Demonstrated at AACR with Pre-clinical Presentations on CFT7455, CFT8634 and CFT1946 – – Cash, Cash Equivalents and Marketable Securities Total $421.7 million as of